Sanofi sells 17 drugs to Neuraxpharm

July 12, 2022

Neuraxpharm has announced that it has entered into a definitive agreement to acquire two product portfolios from Sanofi, as the German-based pharma company looks to strengthen its position as a leading European central nervous system specialist.

The first portfolio combines 15 products addressing CNS disorders and ranging across psychiatry and neurology. Products include Nozinan, Tranxene, Tiapridal, Dogmatil and Largactil. The second portfolio includes two products in pain and vascular diseases — Topalgic and Trental.

"There is significant growth potential in the pharmaceutical sector, especially in the CNS market driven by an ageing population and an increasing awareness of mental health. This phenomenon is a global trend. With the upcoming acquisition, we will not only strengthen our presence in Europe, but also lay the ground for further expanding our international presence," said Neuraxpharm CEO, Jörg-Thomas Dierks.

Sanofi's move is in line with CEO Paul Hudson’s more streamlined product strategy. Back in June, the drugmaker granted long-time partner Regeneron worldwide exclusive license rights to skin cancer treatment, Libtayo for an upfront payment of $900 million and an 11% royalty on worldwide sales.